03
Nov
Nov
Preoperative therapy with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab resulted in tumor management in 55% of sufferers with stage 3 cutaneous melanoma, in keeping with outcomes of a single-arm section 2 medical trial led by the college of Pittsburgh, UPMC Hillman Most cancers Heart and the Nationwide Most cancers Institute (NCI). […]